Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceramide nanoliposomal - PendreaBio

Next Previous
Drug Profile

Ceramide nanoliposomal - PendreaBio

Alternative Names: Ceramide NanoLiposome; Ceraxa; Ceraxa #1; Ceraxa #2; CNL; KN 001; KN-001 - PendreaBio; KN-01; Nanoliposomal ceramide; PB-1001; PB-1002

Latest Information Update: 28 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Keystone Nano
  • Developer PendreaBio; University of Virginia
  • Class Antineoplastics; Ceramides; Neuroprotectants; Sphingolipids
  • Mechanism of Action Undecaprenyl pyrophosphate synthetase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Acute myeloid leukaemia; Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Acute myeloid leukaemia; Prostate cancer

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for preclinical development in Prostate-cancer in USA
  • 01 Nov 2023 Keystone Nano completes a phase I/II trial in Solid tumours (Late-stage disease) in USA (IV) (NCT02834611)
  • 28 Oct 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (Liposomal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top